Avalo Therapeutics, Inc.
AVTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001534120
In the last 90 days, Avalo Therapeutics, Inc. insiders filed 0 open-market purchases and 9 sales; 126 institutions reported holding it in 13F filings for Q2 2026, worth $1.31B in total; no superinvestor holds it.
13F holders, Q1 2026
Institutional positions in Avalo Therapeutics, Inc. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 97
- +14 vs. Q4 2025
- Shares held
- 31.5M
- +12.4M (+64.9%) vs. Q4 2025
- Total value
- $469.6M
- +$123.0M (+35.5%) vs. Q4 2025
- New holders
- 33
- 30 more added
- Sold out
- 19
- 20 more reduced
1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting AVTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 126 | $1.31B |
| Q1 2026 | 97 | $469.6M |
| Q4 2025 | 84 | $361.1M |
| Q3 2025 | 66 | $194.7M |
| Q2 2025 | 36 | $39.1M |
| Q1 2025 | 34 | $66.1M |
| Q4 2024 | 33 | $56.0M |
| Q3 2024 | 29 | $63.2M |
| Q2 2024 | 21 | $9.62M |
| Q1 2024 | 18 | $1.90M |
| Q4 2023 | 12 | $209.4K |
| Q3 2023 | 28 | $158.9K |
| Q2 2023 | 26 | $862.7K |
| Q1 2023 | 32 | $16.0M |
| Q4 2022 | 28 | $28.0M |
| Q3 2022 | 27 | $18.4M |
| Q2 2022 | 54 | $34.7M |
| Q1 2022 | 71 | $56.2M |
| Q4 2021 | 75 | $136.0M |
| Q3 2021 | 77 | $175.5M |
| Q2 2021 | 71 | $218.1M |
| Q1 2021 | 70 | $180.4M |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding Avalo Therapeutics, Inc.; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −210,994−100.0% | Sold out |
| SummitTX Capital, L.P. | 0 | $0 | 0.00% | −195,873−100.0% | Sold out |
| Superstring Capital Management LP | 0 | $0 | 0.00% | −153,313−100.0% | Sold out |
| Squadron Capital Management LLC | 0 | $0 | 0.00% | −130,000−100.0% | Sold out |
| Fred Alger Management, LLC | 0 | $0 | 0.00% | −80,092−100.0% | Sold out |
| Sio Capital Management, LLC | 0 | $0 | 0.00% | −72,173−100.0% | Sold out |
| Woodline Partners LP | 0 | $0 | 0.00% | −52,041−100.0% | Sold out |
| Atom Investors LP | 0 | $0 | 0.00% | −51,194−100.0% | Sold out |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −49,400−100.0% | Sold out |
| Walleye Capital LLC | 0 | $0 | 0.00% | −41,693−100.0% | Sold out |
| Ikarian Capital, LLC | 0 | $0 | 0.00% | −31,106−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −8,737−100.0% | Sold out |
| Belvedere Trading LLC | 0 | $0 | 0.00% | −4,526−100.0% | Sold out |
| Acadian Asset Management LLC | 0 | $0 | 0.00% | −1,471−100.0% | Sold out |
| Citigroup Inc | 0 | $0 | 0.00% | −1,143−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Vanguard Group Inc | – | – | – | – | Not filed |